- Home
- ELVN vs ALX Comparison
ELVN vs ALX Comparison
Compare ELVN & ALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- ALX
- Stock Information
- Founded
- ELVN 2016
- ALX 1928
- Country
- ELVN United States
- ALX United States
- Employees
- ELVN N/A
- ALX N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- ALX Real Estate Investment Trusts
- Sector
- ELVN Health Care
- ALX Real Estate
- Exchange
- ELVN Nasdaq
- ALX Nasdaq
- Market Cap
- ELVN 1.1B
- ALX 1.1B
- IPO Year
- ELVN 2020
- ALX N/A
- Fundamental
- Price
- ELVN $21.86
- ALX $192.37
- Analyst Decision
- ELVN Strong Buy
- ALX Sell
- Analyst Count
- ELVN 5
- ALX 1
- Target Price
- ELVN $37.80
- ALX $125.00
- AVG Volume (30 Days)
- ELVN 220.2K
- ALX 12.2K
- Earning Date
- ELVN 03-13-2025
- ALX 02-10-2025
- Dividend Yield
- ELVN N/A
- ALX 9.36%
- EPS Growth
- ELVN N/A
- ALX N/A
- EPS
- ELVN N/A
- ALX 9.25
- Revenue
- ELVN N/A
- ALX $233,399,000.00
- Revenue This Year
- ELVN N/A
- ALX N/A
- Revenue Next Year
- ELVN N/A
- ALX N/A
- P/E Ratio
- ELVN N/A
- ALX $20.84
- Revenue Growth
- ELVN N/A
- ALX 8.52
- 52 Week Low
- ELVN $10.90
- ALX $184.76
- 52 Week High
- ELVN $30.03
- ALX $251.63
- Technical
- Relative Strength Index (RSI)
- ELVN 44.27
- ALX 41.59
- Support Level
- ELVN $21.45
- ALX $190.48
- Resistance Level
- ELVN $22.82
- ALX $196.39
- Average True Range (ATR)
- ELVN 1.55
- ALX 4.13
- MACD
- ELVN 0.00
- ALX 1.13
- Stochastic Oscillator
- ELVN 32.63
- ALX 47.50
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.